These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22070858)

  • 1. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.
    Arhin FF; Sarmiento I; Parr TR; Moeck G
    Int J Antimicrob Agents; 2012 Feb; 39(2):159-62. PubMed ID: 22070858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.
    Arhin FF; McKay GA; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Int J Antimicrob Agents; 2009 Dec; 34(6):550-4. PubMed ID: 19818587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Sweeney D; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Feb; 87(2):121-128. PubMed ID: 27890418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.
    Arhin FF; McKay GA; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):207-10. PubMed ID: 19748436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
    Vidaillac C; Parra-Ruiz J; Rybak MJ
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
    Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
    Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2013 Apr; 41(4):397-8. PubMed ID: 23374976
    [No Abstract]   [Full Text] [Related]  

  • 18. Extracellular and intracellular bactericidal activities of XF-70 against small-colony variant hemB mutants of meticillin-susceptible and meticillin-resistant Staphylococcus aureus.
    Vaudaux P; Huggler E; Rhys-Williams W; Love WG; Lew DP
    Int J Antimicrob Agents; 2011 Jun; 37(6):576-9. PubMed ID: 21414759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
    Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
    J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.